About REPRIEVE: People living with HIV are at risk of developing cardiovascular disease. To determine whether a statin medication (pitavastatin) would reduce major adverse cardiovascular events (for example, heart attacks and strokes) in PWH, the Randomized Trial to Prevent Vascular Events (REPRIEVE) enrolled a representative sample of PWH for whom statin treatment is not typically recommended under current guidelines. The goal of the study was to find out if pitavastatin reduced major adverse cardiovascular events. REPRIEVE was stopped early, after about an average of 5 years of follow-up, after demonstrating a clear effect of pitavastatin (vs. placebo) to prevent major adverse cardiovascular events.
The REPRIEVE Trial Team hosted Community Forums to share the primary findings of REPRIEVE and discuss the meaning of the results for people living with HIV. If you were unable to join these forums, slides and recordings of the presentations are available below:
